A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

May 27, 2024

Study Completion Date

May 27, 2024

Conditions
Healthy Participants
Interventions
BIOLOGICAL

mPnC candidate

monovalent pneumococcal conjugate candidate

BIOLOGICAL

mPnC control

monovalent pneumococcal conjugate control

Trial Locations (11)

20520

FVR, Turun rokotetutkimusklinikka, Turku

33100

FVR, Tampereen rokotetutkimusklinikka, Tampere

60100

FVR, Seinäjoen rokotetutkimusklinikka, Seinäjoki

67100

FVR, Kokkolan rokotetutkimusklinikka, Kokkola

90220

FVR, Oulun rokotetutkimusklinikka, Oulu

02230

FVR, Espoon rokotetutkimusklinikka, Espoo

00100

FVR, Etelä-Helsingin rokotetutkimusklinikka, Helsinki

00290

MeVac - Meilahti Vaccine Research Center, Helsinki

04400

FVR, Järvenpään rokotetutkimusklinikka, Järvenpää

85-796

Centrum Medyczne Pratia Bydgoszcz, Bydgoszcz

20-044

"NZOZ Praktyka Lekarza Rodzinnego ESKULAP", Lublin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06116591 - A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers | Biotech Hunter | Biotech Hunter